论文部分内容阅读
目的探讨替米沙坦治疗早期2型糖尿病肾病的实际临床疗效。方法对2010年4月至2011年8月收治早期2型糖尿病肾病患者46例,随机分为治疗组和对照组,每组各23例。两组患者均行控制血压、降血糖等常规治疗。治疗组在常规治疗的基础上,加行替米沙坦治疗。观察两组患者治疗前后血压、尿蛋白、肾功能、血糖的变化,详细统计两组患者的实际临床疗效。结果治疗组治疗前收缩压为139.10mm Hg,治疗后为135.00mm Hg;舒张压治疗前为87.30mm Hg,治疗后为83.40mm Hg;24h尿蛋白治疗前为1.10g,治疗后为0.59g;β2微球蛋白治疗前为3015mg/L,治疗后为2445mg/L;对照组收缩压治疗前为138.40mm Hg,治疗后为129.14mm Hg;舒张压治疗前为86.10mm Hg,治疗后为84.60mm Hg;24h尿蛋白治疗前为1.06g,治疗后为1.12g;β2微球蛋白治疗前为2354mg/L,治疗后为2359mg/L。结论替米沙坦治疗早期2型糖尿病肾病疗效显著,值得临床推广应用。
Objective To investigate the actual clinical efficacy of telmisartan in the treatment of early type 2 diabetic nephropathy. Methods From April 2010 to August 2011, 46 patients with early type 2 diabetic nephropathy were randomly divided into treatment group and control group, with 23 cases in each group. Two groups of patients underwent control of blood pressure, hypoglycemic and other conventional treatment. The treatment group was treated with telmisartan on the basis of routine treatment. The changes of blood pressure, urinary protein, renal function and blood glucose in two groups before and after treatment were observed. The actual clinical efficacy of the two groups were statistically analyzed. Results Before treatment, the systolic blood pressure of the treatment group was 139.10 mm Hg, after treatment was 135.00 mm Hg; the diastolic blood pressure was 87.30 mm Hg before treatment and 83.40 mm Hg after the treatment; 1.10 g before the treatment and 0.59 g after the treatment; β2 microglobulin before treatment was 3015mg / L, after treatment for 2445mg / L; control group systolic blood pressure before treatment was 138.40mm Hg, 129.14mm Hg after treatment; diastolic blood pressure before treatment was 86.10mm Hg, after treatment was 84.60mm Hg; 24h urinary protein before treatment was 1.06g, 1.12g after treatment; β2 microglobulin before treatment was 2354mg / L, after treatment for 2359mg / L. Conclusion Telmisartan treatment of early type 2 diabetic nephropathy significant effect, worthy of clinical application.